Members of Aveo Pharmaceuticals board elected to NAS, IOM, AACR and NFCR

CAMBRIDGE, Mass. Members of the scientific advisory board of a biopharmaceutical company focused on cancer drugs have been elected as members of three national science organizations.

Aveo Pharmaceuticals announced Wednesday that members of the board had been elected to the National Academy of Sciences and the Institute of Medicine and received awards from the American Association for Cancer Research and the National Foundation for Cancer Research.

“Aveo sincerely congratulates our SAB members on these much-deserved acknowledgements of their significant contributions to research and medicine,” Aveo president and CEO Tuan Ha-Ngoc stated. “Aveo is privileged to collaborate with leaders in the field of cancer research as we continue to develop and further our own translation research programs and advance our targeted cancer therapies in the clinic.”

SAB members Douglas Hanahan, Tyler Jacks and David Koch were elected to the NAS during its annual meeting in April. Charles Sawyers and Marie-Josee and Henry Kravis received the 2009 Dorothy P. Landon-AACR Prize for Translational Cancer Research during the AACR’s 100th annual meeting in Denver. Ronald DePinho, a co-founder of Aveo, received the fourth annual Albert Szent-Gyorgi Prize for Progress in Cancer Research from the NFCR. In addition, Hanahan, Sawyers and Raju Kucherlapati were elected as members of the IOM.